Filing Flows › 10x Genomics (TXG) › Q3 2026 › vs Q3 2025
10x Genomics (TXG) Q3 2026 vs Q3 2025 (year over year)
10x Genomics's revenue rose $1.7M (+1%) from $149M in Q3 2025 to $151M in Q3 2026. The biggest changes: Consumables +$6.4M (+5%); Instruments −$5.1M (-43%); Services +$897K (+11%).
10x Genomics, Q3 2026: revenue $151M (+1% year over year), operating margin -10.7%, net loss $19.4M, operating cash flow $15.8M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 9.9% | 28.5% | -18.7 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Single Cell | $93.1M | $92.5M | $620K | +0.7% |
| Spatial | $41.2M | $35.4M | $5.8M | +16% |
| Single Cell | $3.8M | $4.9M | −$1.1M | -23% |
| Spatial | $3.1M | $7.1M | −$4.0M | -57% |
| Consumables | $134M | $128M | $6.4M | +5% |
| Instruments | $6.9M | $12.0M | −$5.1M | -43% |
| Services | $9.0M | $8.1M | $897K | +11% |
| Revenue | $151M | $149M | $1.7M | +1% |
| Net loss | $19.4M | $27.5M | −$8.0M | -29% |
| Costs & expenses | $170M | $181M | −$11.2M | -6% |
| Operating costs | $167M | $181M | −$14.5M | -8% |
| Interest & other, net | $2.4M | −$4.0M | $6.5M | — |
| Income tax | $949K | −$733K | $1.7M | — |
| Cost of revenue | $37.7M | $48.7M | −$11.0M | -22% |
| Research & development | $52.9M | $57.2M | −$4.3M | -7% |
| SG&A | $76.1M | $75.4M | $700K | +0.9% |
| Operating cash sources | $35.3M | $70.7M | −$35.4M | -50% |
| Depreciation & amortization | $9.5M | $10.3M | −$793K | -8% |
| Share-based compensation | $23.1M | $25.3M | −$2.2M | -9% |
| Working capital & other | $2.7M | $35.1M | −$32.5M | -92% |
| Net loss absorbed | $19.4M | $27.5M | −$8.0M | -29% |
| Operating cash flow | $15.8M | $43.2M | −$27.4M | -63% |
| Free cash flow (OCF − capex) | $14.9M | $42.5M | −$27.7M | -65% |
| Capital expenditures | $971K | $687K | $284K | +41% |
Questions
How much did 10x Genomics's revenue grow year over year in Q3 2026?
10x Genomics's revenue rose $1.7M (+1%) from $149M in Q3 2025 to $151M in Q3 2026.
What drove 10x Genomics's revenue change in Q3 2026?
Consumables +$6.4M (+5%); Instruments −$5.1M (-43%); Services +$897K (+11%).